Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Cardio oncology is the branch of cardiology that focuses on the prevention, diagnosis and treatment of cardiovascular diseases in patients with cancer. Cardio oncologists have a special interest in treating patients with heart disease related to cancer treatment. And Cardio-oncology is a specialized field of cardiology that focuses on the cardiac, pulmonary and vascular aspects of cancer therapies. The overall goals are to optimize cancer therapy effects and decrease side effects by understanding how each component of the heart works together to supply critical oxygen and nutrients during chemotherapy therapy.


  • Track 1-1  Chemotherapy
  • Track 1-2  Advanced Cancer Treatment
  • Track 1-3   Cardiac Tumour
  • Track 1-4   Cardiac Neoplasm
  • Track 1-5  Nuclear Cardiology

Cardio toxicology is a specialty in the study of drugs and chemicals that affect the heart. The field incorporates both the classic physiological sciences and pharmacology, with a focus on clinical medicine such as emergency medicine or cardiology, pathology or physical examination. Cardio toxicology is the study of how cardiac disorders, such as arrhythmias and heart failure, affect the body. Cardiologists use cardio toxicology to help determine if a patient has problems such as heart failure, abnormal heart rhythms or the need for an implantable cardiac device (such as pacemakers)

Neurocardiology is a branch of cardiology that includes the neurophysiological, neuroanatomical, and neurological aspects.
It primarily includes the neurological causes of cardiac disorders.
It is investigated in terms of heart interactions with the central and peripheral nervous systems.
Cardiovascular intervention and findings are two clinical issues in neurocardiology.
A brief neuron intervention that can result in arrhythmias and heart failure.

Neuro oncology: This specialty deals with brain and spinal cord neoplasms, which are the most life threatening and dangerous.
The worst malignancy brain cancers are gliomas of the brainstem and pons, glioblastoma multiforme, and high grade astrocytoma.
Survival without treatment is usually limited to a few months, whereas survival with radiation and chemotherapy treatment can last a year or more depending on the immune system.

  • Track 3-1  Cardiovascular Systems
  • Track 3-2  Neurocardiac Axis Link
  • Track 3-3  Cardiovascular Systems
  • Track 3-4  Brain and Spinal cord Neoplasms
  • Track 3-5  Neurological Tumors

Cardiology is a discipline of medicine that focuses on disorders with the heart and other components of the circulatory system. Congenital heart defects, coronary artery disease, heart failure, valvular heart disease, and electrophysiology are all included in this field.

Cardiologists, a subspecialty of internal medicine, are doctors who specialize in this branch of medicine. Pediatric cardiologists are cardiology-focused physicians. Cardiothoracic surgeons, often known as cardiac surgeons, are general surgery specialists who specialize in cardiac surgery.

  • Track 4-1  Congenital heart defects
  • Track 4-2  Coronary artery disease
  • Track 4-3  Heart failure
  • Track 4-4  Valvular heart disease
  • Track 4-5  Electrophysiology

Technology to help patients with arrhythmia disorders control their diseases is growing at such a fast rate that concepts that seemed impossible only a few years ago are already a reality.

Leadless pacemakers, subcutaneous implantable cardioverter defibrillators, subcutaneous implantable loop recorders, and methods to make ablation more effective are among the innovative technology new to the market or in clinical testing.

  • Track 5-1  Tachycardia
  • Track 5-2  Bradycardia
  • Track 5-3  Supraventricular arrhythmias
  • Track 5-4  Ventricular arrhythmias
  • Track 5-5  Bradyarrhythmias

Calcium buildup during a major artery outside the guts may indicate a future attack or stroke. According to researchers, People with abdominal aortic calcification (AAC) have a two to four times increased risk of a future cardiovascular incident. The study also discovered that the more calcium in the blood vessel wall, the higher the chance of future cardiovascular events, and that persons with AAC and chronic kidney illness were at an even higher risk than those without AAC.

Calcium can build up in the blood vessel wall and harden the arteries, obstructing blood flow or causing plaque rupture, both of which are common causes of heart attacks and strokes.

Poor diet, a sedentary lifestyle, smoking, and genetics are all factors that contribute to arterial calcification.

  • Track 6-1  Coronary Artery Disease
  • Track 6-2  Heart Arrhythmias
  • Track 6-3  Heart failure
  • Track 6-4  Heart Valve Disease
  • Track 6-5  Pericardial Disease
  • Track 6-6  Cardiomyopathy
  • Track 6-7  Congenital Heart Disease

Hypertension may be a major risk factor for heart condition and stroke. Around a third of people with hypertension are now undiagnosed, and half of those who have been identified are not taking antihypertensive drugs. The World Health Organization (WHO) estimates that high blood pressure kills at least nine million people worldwide each year, either directly or indirectly.

Our goal is to highlight recent advances in hypertension clinical and basic research, as well as to discuss future paths in the discipline's development and building.

  • Track 7-1  Hypertension-overview
  • Track 7-2  Hypertensive heart disease
  • Track 7-3  Primary and secondary high blood pressure
  • Track 7-4  High blood pressure treatments
  • Track 7-5  High blood pressure medications

Because of its rising prevalence, severe morbidity, high mortality, and fast rising health-care costs, heart failure (HF) is a major cardiovascular illness. The number of people suffering with Heart failure is rising all over the world. Over the last four decades, there have been significant advancements in the definition, diagnostic methods, and management of Heart failure. Biomarkers, imaging, and genetic testing are all being used to improve HF risk categorization.

In clinical practise, newly innovative drugs and equipment for HF have been widely accepted. In addition, final treatment for end-stage heart failure, such as a left ventricular assist device or heart transplantation, is fast evolving.

  • Track 8-1  Atrial Fibrillation
  • Track 8-2  Device Therapy
  • Track 8-3  Chronic Heart Failure
  • Track 8-4  Acute Heart Failure
  • Track 8-5  Valvular Heart Disease
  • Track 8-6  Acute Cardiac Care

Evolved cardiac imaging has advanced greatly as a result of technological improvements, and it now serves as both a diagnostic and a prognostic tool. Regular follow-up imaging, such as echocardiography or more advanced imaging, such as stress imaging, is required for patients with heart failure.

Imaging-guided treatment and interventional procedures help patients with heart failure. The purpose of this research is to provide a comprehensive overview of the most recent imaging modalities for heart failure diagnosis and treatment.

  • Track 9-1  Artificial Intelligence
  • Track 9-2  CT Imaging
  • Track 9-3  CT Calcium Scoring Now Part of Guidelines
  • Track 9-4  Important Cardiology Articles
  • Track 9-5  New Cardiac CT scanner Technology
  • Track 9-6  Advances in Spectral Imaging
  • Track 9-7  Special Sessions for EP and Structural Heart

Progress has been made in research on innovative treatments, mechanical and pharmacological approaches, and repair/regenerative cellular therapy to treat irreversible cardiovascular illnesses such as myocardial infarction. In cellular therapy research, new cellular types are being researched. Although the therapeutic effects of cell therapy are still limited, clinical trial results are encouraging.

This advancement is being aided by advances in stem cell paracrine activity, the use of growth factors, miRNA, and novel biomaterials. In the near future, these therapies should become commonplace in clinical practise.

  • Track 10-1  Percutaneous coronary intervention
  • Track 10-2  Coronary artery bypass grafting
  • Track 10-3  primary coronary event, such as plaque rupture
  • Track 10-4  A problem of oxygen supply and demand
  • Track 10-5  Sudden cardiac death

Pulmonary hypertension is difficult to spot early because it's rarely discovered during a typical physical examination. Even when the disease has progressed, the signs and symptoms are identical to those of other heart and lung diseases.

The field of pulmonary arterial hypertension (PAH) has recently been marked by significant advances in therapy alternatives and, as a result, improved patient outcomes. Our goal is to bring out the latest developments in the treatment of pulmonary heart diseases.

  • Track 11-1  Dyspnea
  • Track 11-2  Pulmonary Embolism
  • Track 11-3  Hypercapnia
  • Track 11-4  Obstructive Sleep Apnea
  • Track 11-5  Chronic Obstructive Pulmonary Disease
  • Track 11-6  Hypoxemia
  • Track 11-7  Hypoxemia
  • Track 11-8  Heart Failure

The most common cause of death in the world is coronary artery disease (CAD). While the symptoms and signs of coronary artery disease are recognised in advanced stages of the disease, most people with the disease show no signs or symptoms for decades as the disease advances before the first manifestation of symptoms, which is typically a "sudden" heart attack, occurs.

Some of these atheromatous plaques may rupture after decades of growth, reducing blood supply to the heart muscle (along with the activation of the blood clotting system). The disease is the leading cause of sudden death, as well as the leading cause of death in men and women over the age of 20.

Individuals with this level of coronary artery disease have often had one or more myocardial infarctions (heart attacks) and may be experiencing signs and symptoms of persistent coronary ischemia, such as angina at rest and flash pulmonary edema.

  • Track 12-1  Obstructive coronary artery disease
  • Track 12-2  Non-obstructive coronary artery disease
  • Track 12-3  Coronary micro vascular disease
  • Track 12-4  Coronary Artery Bypass Surgery
  • Track 12-5  High blood pressure

Cardiovascular diseases (CVDs) are the leading cause of death worldwide, claiming the lives of an estimated 17.9 million people per year. Coronary heart disease, cerebrovascular illness, rheumatic heart disease, and other heart and blood vessel problems are all classified as CVDs. Heart attacks and strokes account for more than four out of every five CVD deaths, with one-third of these deaths occurring before the age of 70.

A variety of laboratory tests and imaging examinations are used to diagnose cardiovascular disorders. The medical and family histories of the patient, risk factors, physical examination, and synchronisation of these findings with the results of tests and procedures are the most important aspects of diagnosis.

  • Track 13-1  Abnormal heart rhythms or arrhythmias
  • Track 13-2  Congenital heart disease
  • Track 13-3  Deep vein thrombosis
  • Track 13-4  Pulmonary embolism
  • Track 13-5  Heart muscle disease

For women, heart disease is the main cause of death. Heart disease affects women in various ways than it does males. Men, for example, have more heart attacks than women, but women die from heart attacks at a higher rate than men. During percutaneous coronary interventions (PCI) using femoral arterial access, women have a greater rate of bleeding. Drug-induced cardiac arrhythmias are also more common in women.

The completed studies have contributed to the establishment of guiding documents for drug and device development for men and women, as well as a better knowledge of cardiovascular disease in women.

  • Track 14-1  Anxiety and Heart Disease
  • Track 14-2  Assessing Cardiovascular Risk with C-Reactive Protein
  • Track 14-3  Depression and Heart Disease
  • Track 14-4  Menopause and the Cardiovascular System
  • Track 14-5  Peripartum Cardiomyopathy
  • Track 14-6  Diabetes and Heart Disease in Women
  • Track 14-7  New Imaging Techniques: Risks and Benefits
  • Track 14-8  Vitamin D and the Heart

Every day, improvements in the field of heart surgery are created. Surgery is becoming easier and safer, and recovery is becoming faster and less painful, due to advances in technology. New and creative techniques for minimally invasive operations, cutting-edge technologies, and clinical trials are all helping to advance the science of heart surgery in Beaumont, reducing recovery periods and making heart surgery less painful for patients.

With the introduction of newer immunosuppressive drugs and procedures that may potentially result in tolerance, the future of heart transplantation seems bright. A improved knowledge of acute and chronic rejection pathways through basic science investigations supports much of this improvement in heart transplant treatment. Personalized medicine will be a part of the future, with genetics and molecular research dictating specific treatment for best results.

  • Track 15-1  Coronary artery bypass grafting
  • Track 15-2  Heart valve repair or replacement
  • Track 15-3  Insertion of a pacemaker or an implantable cardioverter defibrillator
  • Track 15-4  Maze surgery
  • Track 15-5  Aneurysm repair
  • Track 15-6  Heart transplant
  • Track 15-7  Insertion of a ventricular assist device (VAD) or total artificial heart (TAH)

For the assessment of patients with valvular heart disease, echocardiography is the preferred imaging modality. Advances in echocardiography may have a significant impact on the assessment and treatment of individuals with valvular heart disease.

This review will highlight the current research on improvements in this patient population, including three-dimensional echocardiography, strain imaging, intracardiac echocardiography, and fusion imaging.

  • Track 16-1  Cardiomyopathies
  • Track 16-2  Diseases of the aorta
  • Track 16-3  Transesophageal echocardiography
  • Track 16-4  Stress echo echocardiography
  • Track 16-5  Computed tomography

Clinical cardiology is a specialty of medicine that focuses on the diagnosis and treatment of cardiovascular disorders. Interventional cardiology, cardiac electrophysiology, echocardiography, and nuclear cardiology are all common specialties for cardiologists. When it comes to cardiac diseases, each of these specialty has its own set of techniques.

This session will have a big impact on cardiac research in the future. Cardiology is the study of heart diseases and disorders such coronary artery disease and congestive heart failure. Congenital heart defects, coronary artery disease, heart failure, vascular heart disease, and electrophysiology are all covered within clinical cardiology.

  • Track 17-1  Acute Coronary Syndromes
  • Track 17-2  Heart Failure and Cardiomyopathies
  • Track 17-3  Geriatric Cardiology
  • Track 17-4  Arrhythmias and Clinical EP
  • Track 17-5  Invasive Cardiovascular Angiography and Intervention
  • Track 17-6  Valvular Heart Disease

By providing their important clinical examples of late occurrence, cardiology case reports provide an ideal assemblage for all cardiologists. Clinicians, students, and paramedical staff members gain significant experience through studying medical cases.

Rare medical reports and conditions uncovered using cutting-edge examination techniques are supported. Furthermore, studying diagnostic procedures from medical cases and symptom interpretation is important for training and improving the processes employed in the clinical field.

  • Track 18-1  Case reports on Cardiac surgery
  • Track 18-2  Case reports on Vascular heart disease
  • Track 18-3  Case reports on Hypertension and Healthcare
  • Track 18-4  Case reports on Cardiac and Cardiovascular research
  • Track 18-5  Case reports on Pediatric Cardiology
  • Track 18-6  Case reports on Heart diagnosis
  • Track 18-7  Case reports on Heart disease & Failure
  • Track 18-8  Case reports on Atherosclerosis
  • Track 18-9  Case reports on Heart devices

Interventional cardiology could also be a rapidly expanding specialty. This expansion is thanks to advancements in existing technology, the creation of the latest technologies, and thus the extension of patient selection criteria.

Recent randomized studies examining the efficacy of revascularization or medical treatment in stable ischemic heart disease, the treatment of acute coronary syndromes, emerging interventional devices, adjunctive pharmacotherapy, and intravascular imaging and physiology guidance have advanced the evidence-based knowledge in interventional cardiology significantly.

  • Track 19-1  Ischemic heart diseases
  • Track 19-2  Angiogram
  • Track 19-3  Angioplasty
  • Track 19-4  Disorders of heart valves
  • Track 19-5  Valvuloplasty

In the past year, significant progress has been made in the field of paediatric cardiology, Several clinical studies and the issuance of expert understandings in various subspecialties proving to be invaluable in improving the diagnosis and treatment of cardiovascular disease in children.

Paediatric cardiology is concerned with cardiac disorders in children who are still growing and developing. In order to provide all-around patient care, paediatric cardiologists need a strong background in general paediatrics as well as knowledge in cardiac disease.


  • Track 20-1  Fetal cardiology
  • Track 20-2  Arrhythmias
  • Track 20-3  Pediatric cardiac imaging
  • Track 20-4  Multicenter heart failure
  • Track 20-5  Quality Improvement

Cardiovascular pharmacotherapy is still a very active field. The goal of this study is to outline recent key breakthroughs in cardiovascular pharmacotherapy, with an emphasis on a recently approved medicine for heart failure treatment.

Heart failure is a prominent cause of morbidity and mortality globally, despite all breakthroughs in pharmacological and therapeutic treatment. To treat heart failure, many new therapeutic advance tactics have been investigated, including cell transplantation, gene delivery or therapy, and cytokines or other small chemicals.

  • Track 21-1  Cotransporter
  • Track 21-2  Endothelial Progenitor Cell
  • Track 21-3  Blood Pressure
  • Track 21-4  Actinobacteria
  • Track 21-5  Leporidae

Artificial intelligence, digital health technology, and mobile devices will transform cardiovascular care in the future as a way to prevent and treat heart disease.

The heart's sound, rhythm, pace, structure, and function are all monitored in order to maintain it healthy for as long as feasible. To prevent stroke, heart attack, heart failure, or any other cardiovascular risk, an army of digital health technology has recently joined forces with traditional cardiology preventive techniques. Miniature sensors, digital twins, and artificial intelligence could help them in the future.

Let's take a look at what the future of cardiology may hold!

  • Track 22-1  Innovative imaging and device technologies
  • Track 22-2  Surgical and interventional approaches
  • Track 22-3  New diagnostic methods, screening, and patient classification are all being explored.
  • Track 22-4  Cardiology personalised medication
  • Track 22-5  Therapeutic overviews showcasing the best treatment options and future possibilities
  • Track 22-6  Evidence from the real world and outcomes research

Heart disease is treated with a variety of medications. It's crucial for persons with heart disease and those who care for them to understand their medications, read the labels, and be aware of any potential side effects.

Physical examination findings, interviews with the patient and his or her family, a patient's and family history, and clinical findings in laboratory and radiographic examinations are all used to make a medical diagnosis. Imaging techniques, surgery, electrophysiology, angiography, radiography, and other approaches can all be used to diagnose cardiac disease. Following a heart disease diagnosis, hospital treatment is essential.

  • Track 23-1  Echocardiogram
  • Track 23-2  Cardiac Catheterization
  • Track 23-3  Electrophysiology Test
  • Track 23-4  CT Heart Scan
  • Track 23-5  Myocardial Biopsy
  • Track 23-6  Pericardiocentesis

Heart failure and death are caused by the heart's limited regeneration capacity. It's difficult for cardiac cells to recover once they've been diseased, similar to how your body would heal a wound. For researchers interested in creating and regenerating heart cells, studying how the heart develops in babies and then adults is a natural next step.

They're also looking into how stem cell-derived cardiac cells heal damaged hearts and whether they may be used to treat heart muscle problems.


  • Track 24-1  Adult stem cells
  • Track 24-2  Pluripotent stem cells
  • Track 24-3  Cardiac Stem-Ness
  • Track 24-4  Applications of PSCs in cardiovascular research
  • Track 24-5  Translational potential of PSC
  • Track 24-6  Pluripotent stem cells in first human trials